What are the benefits of AI in medcomms?

Anthony Stackman · 18 Oct 2026

AI delivers real, measurable benefits in medical communications — from accelerating content production and supporting literature reviews to enabling more personalised engagement with healthcare professionals and patients. The gains are most significant when AI tools are deployed strategically, with human scientific and regulatory oversight intact. This article works through the questions medcomms professionals are asking about AI right now.

How is AI currently being used in medical communications?

AI is being used across the medcomms workflow in 2026, spanning literature surveillance, content drafting, translation, data visualisation, and audience segmentation. The most widely adopted applications sit at the production end: large language models that accelerate first-draft generation, and machine learning tools that monitor scientific literature for relevant publications in near real time.

In medical affairs, AI-powered platforms are helping teams synthesise evidence faster, identify emerging safety signals, and prepare MSL briefing documents at scale. On the commercial side, AI is supporting modular content frameworks, where approved claims and references are assembled into tailored outputs for different audiences and markets without rebuilding from scratch each time.

Congress support is another growth area. AI tools are being used to monitor real-time data presentations, generate rapid summaries of poster sessions, and prepare reactive materials for medical information teams. The technology is also appearing in regulatory submission workflows, where natural language processing helps teams cross-reference labelling language and identify inconsistencies across large document sets.

What is consistent across all these use cases is that AI functions as an accelerant, not an autonomous author. Experienced medical writers, strategists, and medical affairs professionals remain responsible for the accuracy, tone, and compliance of every output.

How does AI improve speed and efficiency in medcomms content production?

AI compresses time spent on tasks that are high-volume but low-creativity: literature searching, reference formatting, first-draft generation, and translation. What previously took a medical writer several days can, with the right tools and governance in place, be reduced to hours — freeing expert time for work that genuinely requires scientific judgement.

Modular content is where efficiency gains are most tangible at scale. AI can help agencies and medical affairs teams manage large libraries of approved content modules, automatically flagging when claims require updating following new data or label changes. For global programmes operating across multiple markets, intelligent content management reduces duplication and cuts the time between data generation and field-ready materials.

Localisation is another area where AI is making a meaningful difference. Machine translation, when reviewed and validated by medically qualified linguists, can significantly reduce turnaround times for multi-market rollouts. That qualifier matters: raw AI translation of medical content without expert oversight remains a compliance risk, not a shortcut.

Efficiency gains depend heavily on how well AI tools are integrated into existing workflows and governance structures. Teams that have invested in clear processes for AI use tend to see the strongest productivity improvements; those treating AI as an ad hoc resource often find time savings offset by additional review cycles.

Can AI improve scientific accuracy in medical writing?

AI can support scientific accuracy in medical writing, but it cannot guarantee it — and conflating the two is one of the most important risks in medcomms AI adoption. AI tools can reduce human error in specific, bounded tasks: checking that references are correctly cited, identifying inconsistencies between a claim and its source, or flagging whether a statistical interpretation aligns with the underlying data. These are genuine and valuable contributions.

Where AI falls short is in the contextual scientific judgement that experienced medical writers bring. An AI model may correctly reproduce a finding from a clinical trial abstract without understanding the limitations of that trial’s design, the broader evidence landscape, or the regulatory implications of how that finding is framed. It can produce text that reads as authoritative while being subtly misleading — and in regulated healthcare communications, subtly misleading is a serious problem.

The most responsible approach treats AI as a quality support tool rather than a quality assurance mechanism. AI-assisted literature checks and reference validation add a useful layer of review, but they supplement rather than replace the expert scientific review that medcomms content requires before it reaches a healthcare professional or patient.

There is also the question of training data currency. Large language models have knowledge cutoffs, which means they may not reflect the most recent clinical trial data, updated guidelines, or revised product labelling. For a field where current evidence is often the most critical, this is a limitation that teams need to actively manage.

What are the risks of using AI in regulated medical communications?

The primary risks are content accuracy failures, compliance breaches, and the erosion of accountability. Medcomms content operates within strict regulatory frameworks — including ABPI, FDA, EMA, and market-specific codes — so any AI-generated output that introduces unsupported claims, misrepresents data, or uses unapproved language carries real consequences for both agency and client.

Hallucination and factual error

Large language models can generate plausible-sounding but factually incorrect content, a phenomenon known as hallucination. In a consumer context this is a quality problem; in medical communications it is a patient safety and regulatory risk. Reference fabrication is a documented failure mode: AI systems have produced citations that do not exist, or attributed findings to studies that say something materially different. Every AI-assisted output in medcomms requires rigorous human verification against primary sources.

Compliance and data governance

Using commercial AI tools to process confidential client data, unpublished clinical data, or commercially sensitive information raises significant data governance questions. Teams need to understand where their data goes, how it is stored, and whether using a particular AI platform is consistent with client confidentiality agreements and applicable data protection regulations. This is a live contractual and legal issue that requires proper due diligence before any AI tool is deployed on client work.

There is also a broader accountability question. Regulatory codes hold companies and their agencies responsible for the accuracy and appropriateness of communications. “The AI wrote it” is not a defensible position. Clear internal policies on AI use, human sign-off requirements, and audit trails are not optional extras — they are the minimum governance standard for responsible AI deployment in this sector.

How does AI support personalised HCP and patient engagement?

AI enables content to be tailored at a scale that was previously impractical. For HCP engagement, this means delivering the right scientific content to the right specialist at the right point in their decision-making journey — based on specialty, prescribing behaviour, previous interactions, and the specific data they have engaged with. For patient communications, it means adapting health information to literacy level, language, condition stage, and communication preference.

AI-driven segmentation is making omnichannel medical affairs programmes significantly more sophisticated. Rather than sending the same clinical data package to every cardiologist on a list, teams can identify which HCPs are most likely to be receptive to specific messages based on their engagement history, and sequence content accordingly. This has genuine scientific value when the right clinical evidence reaches the clinicians most actively treating the relevant patient population.

For patient engagement, AI is enabling more responsive and accessible communications. Intelligent chatbots and symptom-checking tools — when built on validated clinical content and deployed with appropriate medical oversight — can provide patients with relevant, timely information when they need it most. Disease awareness programmes are also beginning to use AI to personalise content journeys based on where an individual is in their diagnosis or treatment experience.

The ethical dimension deserves attention. Personalisation in healthcare communications must be built on transparency, consent, and genuine benefit to the recipient — not optimised purely for engagement metrics. The most effective personalised medcomms programmes are those where personalisation serves the patient or clinician’s informational needs, rather than simply maximising time spent with brand content.

Should medcomms agencies adopt AI now or wait?

Agencies should be adopting AI now — selectively, with clear governance, and with a realistic understanding of where it adds value and where it introduces risk. Waiting is not a neutral position. Agencies that delay building AI literacy and workflow integration are already falling behind on efficiency, and the gap will widen as tools mature and competitors embed them more deeply into their production processes.

The case for acting now is not that AI is fully mature for medcomms — it is not. The case is that the agencies best positioned to use AI responsibly in the future are those building internal knowledge, governance frameworks, and practical experience today. That means running structured pilots on appropriate content types, developing clear policies on which AI tools can be used for which tasks, and investing in training so that medical writers and strategists understand both the capabilities and the failure modes of the tools they are working with.

The areas where adoption makes most immediate sense are those where AI augments rather than replaces expert judgement: literature monitoring, reference checking, modular content management, translation support, and internal briefing documents. These are lower-risk entry points that deliver genuine efficiency gains without exposing clients to the compliance risks that come with AI-generated promotional or regulatory content that has not been rigorously reviewed.

What agencies should not do is adopt AI reactively — under competitive pressure, without the governance infrastructure to use it safely. The reputational and regulatory consequences of a compliance failure in medcomms are severe enough that quality of adoption matters far more than speed.

How Wizzard approaches AI in medical communications

We bring together scientific expertise, creative thinking, and strategic rigour to help pharmaceutical companies, biotech startups, and healthcare organisations communicate more effectively. Our approach to AI reflects the same principles that guide all of our work:

Human oversight at every stage: AI tools support our medical writers and strategists — they do not replace the expert review that regulated content requires
Governance before deployment: we evaluate AI tools against client confidentiality, data protection, and compliance requirements before integrating them into any client workflow
Creativity informed by science: our “Human-Made Magic” philosophy means we use AI to create space for bigger, brighter, braver ideas — not to produce generic output at volume
Practical efficiency gains: from literature surveillance to modular content frameworks, we apply AI where it genuinely accelerates delivery without compromising quality

If you are thinking about how AI could strengthen your medical communications programme without introducing unnecessary risk, we would be glad to have that conversation. Get in touch with the Wizzard team to explore what a smarter, more creative approach to medcomms could look like for your organisation.